User:Sofiaebeo/GLP-1 receptor agonist

Cardiovascular disease
GLP-1 agonists have demonstrated a cardioprotective effect when used to treat obesity. Moreover, SGLT2 inhibitors like Dapagliflozin and Empagliflozin have demonstrated significant benefits in decreasing mortality and hospitalization rates among individuals with Heart Failure and Reduced Ejection Fraction, irrespective of their diabetic status.